http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#type type

http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement Statement

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/2000/01/rdf-schema#label label

etidronate disodium tablets usp are indicated for the treatment of symptomatic paget s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury etidronate disodium tablets are not approved for the treatment of osteoporosis etidronate disodium tablets are indicated for the treatment of symptomatic paget s disease of bone etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by in addition reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients in many patients the disease process will be suppressed for a period of at least one year following cessation of therapy the upper limit of this period has not been determined the effects of the etidronate disodium treatment in patients with asymptomatic paget s disease have not been studied however etidronate disodium treatment of such patients may be warranted if extensive involvement threatens irreversible neurologic damage major joints or major weight bearing bones etidronate disodium tablets are indicated in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury etidronate disodium tablets reduce the incidence of clinically important heterotopic bone by about two thirds among those patients who form heterotopic bone etidronate disodium tablets retard the progression of immature lesions and reduces the severity by at least half follow up data at least 9 months post therapy suggests these benefits persist in total hip replacement patients in spinal cord injury patients

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#object object

http://purl.obolibrary.org/obo/DOID_5408 DOID_5408

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate predicate

https://w3id.org/biolink/vocab/treats treats

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

http://www.w3.org/1999/02/22-rdf-syntax-ns#subject subject

https://identifiers.org/drugbank:DB01077 drugbank:DB01077

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/association_type association_type

https://w3id.org/biolink/vocab...OrPhenotypicFeatureAssociation ChemicalToDiseaseOrPhenotypicFeatureAssociation

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/provided_by provided_by

https://w3id.org/um/NeuroDKG NeuroDKG

Leoni Bücken

2021-06-13T10:30:04.305Z

http://purl.org/np/RAAKC0Z4ky... RAAKC0Z4ky

links a nanopublication to its assertion http://www.nanopub.org/nschema#hasAssertion assertion

https://w3id.org/biolink/vocab/relation relation

https://w3id.org/um/neurodkg/SymptomaticReliefIndication SymptomaticReliefIndication

Leoni Bücken

2021-06-13T10:30:04.305Z